Welcome to the Carcinoid Cancer Awareness Network!
CCAN was awarded 2014 Top Rated Non Profit by Great Non profits. A Big thanks to all our supporters and the community!
Maryann Wahmann Founder of CCAN and the 2010 recipient of the Warner advocacy award.
WHAT IS CARCINOID CANCER? Carcinoid is part of a group of tumors called neuroendocrine tumors that grow in the hormone producing cells, is listed with the National Organization of Rare Disorders.
Because neuroendocrine (NET) cancer is considered rare and due to a lack of public awareness the disease has had a low priority for medical research. Current studies suggest that Carcinoid and Neuroendocrine tumors are not as rare once thought.
Over 11,000 new patients are diagnosed each year and as many as 125,000 patients are living in the US today- AND the number of diagnoses is increasing by more than 5% annually.
Carcinoid/NETs are also regularly overlooked during the diagnostic process. Many patients go untreated for years and have been told the have another disease. However, due to the generosity and selfless effort of many people, progress IS being made!
If the tumors are found early and you get proper treatment, you can live a long life. There are many 20 year survivors living in the USA. Failure to diagnose the disease and provide proper treatment, however, has the most serious consequence.
Information & encouragement for
Carcinoid & other Neuroendocrine Cancer patients, their families.
Speak to the 2010 Warner Advocacy Award winner:
Maryann Wahmann a patient or caregiver call toll free:
9 am - 9 pm EST 866-850-9555.
For your FREE information packet please e-mail us with your name address and telephone number !
New Cancer Awareness T-shirt for sale!
See in the Zebra Store!
2015 Conference Series
Locations and Agenda to be announced December 2014
New York Carcinoid/NET Support Group
Meeting will be held on
December 7, 2014
1:30 PM - 4:30 PM
At The Monter Cancer Center
450 Lakeville Rd Lake Success, NY 11042
The North American Neuroendocrine Tumor Society
Guidelines for diagnosis and treatment of NET Tumors.